Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Are there studies looking at Ra-223 and SBRT for oligometastatic disease in the setting of mCRPC?
Answer from: Radiation Oncologist at Community Practice
Yes, quite a few including one from UCLA- NCT05496959
Sign in or Register to read more
18046
Related Questions
How would you optimally boost patients with high or very high risk prostate cancer receiving definitive radiotherapy in 2025?
Would you treat a patient with evidence of prostate cancer who refuses biopsy?
What is your preferred dose to gross lymph nodes when treating non-metastatic high-risk prostate cancer?
Do you need renal biopsy before SBRT for RCC suspicious cancer?
How would you approach a patient with prostate cancer with PSMA+ non-regional lymph nodes?
In patients with high risk prostate cancer and involved common iliac lymph nodes would you recommend radiation?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
Given the different rates of testosterone recovery, do you alter the duration of ADT when using Leuprorelin (GnRH Agonist) vs relugolix (GnRH antagonist) in patients with intermediate or high-risk prostate cancer who received definitive radiation?
Do you include the prostate when treating bladder cancer?
For recurrent prostate cancer after prostatectomy with soft tissue mass in the prostate fossa, is hypofractionation an option or is standard fractionation recommended?